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Aims/hypothesis—To determine the associations of baseline depression symptoms and use of
antidepressant medicines (ADMs) with baseline cardiovascular disease (CVD) risk factors in Look
AHEAD (Action for Health in Diabetes) trial participants.
Methods—Look AHEAD participants (n=5,145; age 58.7± 6.8 years; BMI 35.8±5.8 kg/m2) were
assessed for CVD risk factors (elevated HbA1c or insulin use, elevated BP or antihypertensive use,
elevated lipid levels or lipid-lowering medication, current smoking, BMI ≥30 kg/m2, lower peak
exercise capacity assessed as metabolic equivalents [METs], and ankle–brachial index <0.9 or
>1.3). Participants also completed the Beck Depression Inventory (BDI) and reported their use of
ADMs.
Results—Of the participants, 14.7% had BDI scores ≥11, consistent with mild-moderate
depression, and 16.5% took ADMs; 4.4% had both depression markers (i.e. elevated symptom
scores and took ADMs). In logistic regression analyses of CVD risk (elevated risk factor or use of
medication to control the risk factor), controlled for demographic factors, continuous BDI scores
and ADM use were each independently associated with elevated BP (or medication), current
smoking, BMI ≥30 kg/m2 and lower MET values. ADM use was also associated with elevated
serum lipids or use of lipid-lowering medication.
Conclusions/interpretation—Among Look AHEAD participants, depression symptoms or
ADM use on entry to the study were each independently associated with a wide range of CVD risk
factors. Future research should assess the temporal dynamics of the relationships of depression
symptoms and ADM use with CVD risk factors.
Keywords
Antidepressant medication; CVD risk; Depression symptoms; Look AHEAD trial
Introduction
Rates of cardiovascular disease (CVD) and CVD mortality are disproportionately high in
people with diabetes [1]. This fact may be explained in part by the disproportionately high
rates of depression in this population [2], since depression is associated with adverse CVD
outcomes [3, 4]. Mechanisms underlying the associations among diabetes, depression and
CVD have not been determined; while many suggestions have been made, perhaps the most
straightforward is that depression is linked to a variety of known CVD risk factors, e.g.
physiological risk factors (glucose, BP, lipids and obesity), as well as behaviours such as
cigarette smoking, decreased physical activity and poor diet.
It is also unclear whether the use of antidepressant medicines (ADMs) affects CVD risk.
Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors affect cardiac
conduction and rhythm, and cardiotoxic side effects of these medicines have been reported
[5]. Use of newer, more commonly prescribed ADMs, such as selective serotonin reuptake
inhibitors (SSRIs) and serotonin–noradrenaline (norepinephrine) reuptake inhibitors
(SNRIs), may reduce platelet aggregation and improve cardiovascular morbidity and
mortality in patients with established CVD [5]. However, these benefits have not been found
in all studies, and they appear to be minimal when they are present [6, 7].
The possibility that ADM usage might be associated with negative health outcomes was
raised by findings from the Diabetes Prevention Program (DPP), which showed that
participants in the placebo and intensive lifestyle intervention (ILI) arms of the study were
two to three times more likely to develop diabetes during the course of the study if they were
taking ADMs than if they were not [8]. The risk of developing diabetes in the DPP
metformin group was not elevated among those taking ADMs. The possible health
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consequences of ADM use in people with type 2 diabetes deserve further study—if people
with diabetes take ADMs at the same rate as the general population (15%), approximately
three million people in the USA who have type 2 diabetes are taking ADMs.
To date there have been few, if any, studies on the association of depression symptoms or
ADM use with CVD risk in people with type 2 diabetes, or studies—among people with
diabetes or in the general population—that simultaneously assess the independent
association of depression symptoms and ADM use with CVD risk.
The Look AHEAD (Action for Health in Diabetes) clinical trial offers an opportunity to
assess the independent association of depression symptoms and ADM use with CVD-related
behavioural and clinical risk factors (smoking, fitness and BMI, and blood glucose, lipids
and BP), controlled for potential confounders. Based on the existing literature we
hypothesise a significant positive association between depression symptoms and CVD risk
factors in the Look AHEAD participants, as well as a significant positive association
between ADM use and CVD risk factors. Moreover, we hypothesise that these associations
will be additive, such that neither association is contingent upon the other. Since this is a
cross-sectional study we cannot draw conclusions about causal associations between
depression measures and CVD risk measures, but the results of this study can generate
hypotheses to be tested in future longitudinal studies.
Methods
The primary objective of the Look AHEAD trial is to assess the long-term effect (up to 14
years) on cardiovascular and other health outcomes of a comprehensive behavioural weight
loss intervention in a randomised clinical trial of 5,145 overweight or obese individuals with
type 2 diabetes. Participants were randomised to an ILI or to a usual care intervention,
referred to as diabetes support and education. Participants are being followed at 16 clinical
centres in the USA. On entry to the study Look AHEAD trial participants were 45–76 years
of age (which was changed to 55–76 years during the second year of recruitment to increase
the anticipated cardiovascular event rate). Participants had a BMI >25 kg/m2 (27 kg/m2 if
currently taking insulin, because insulin use is known to increase weight), HbA1c <11%,
systolic BP <160 mmHg and diastolic <100 mmHg and triacylglycerols <6.78 mmol/l.
Potential participants were excluded if they had underlying diseases likely to affect the
safety of the interventions or factors that might limit adherence to the interventions or affect
conduct of the trial, including hospitalisation for depression in the past 6 months, suicidal
ideation, current diagnosis of schizophrenia, other psychotic disorders or bipolar disorder,
self-report of alcohol or substance abuse within the past 12 months, or other medical,
psychiatric or behavioural limitations (e.g. difficulty completing the 2 week run-in period
during which participants were required to record food eaten) that in the judgement of the
principal investigator might interfere with study participation or the ability to follow the
protocol. ADM use and depression symptoms that did not require hospitalisation in the prior
6 months and did not involve suicidal ideation were not criteria for exclusion. Full details of
the Look AHEAD design and methods are reported elsewhere [9]; however, measures
relevant to this report are briefly described below.
Assessments
Anthropometry—At the beginning of the study, all participants were assessed for weight,
height, BP and ankle–brachial index (ABI). Weight and height were assessed in duplicate
using a digital scale and a standard stadiometer. Seated BP was also measured in duplicate
using an automated device after a 5 min rest. Leg-specific ABI was calculated according to a
standard algorithm reported elsewhere [10].
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Fitness—Participants completed a maximal graded exercise test to assess fitness before
randomisation. Fitness was assessed using a standardised maximum graded exercise test and
expressed as metabolic equivalents (METs): 1.0 MET is approximately 3.5 ml oxygen
uptake (kg body weight)−1 min−1. Details of the test were reported earlier [11].
Serum measurements—Standardised analyses of frozen specimens were conducted at
the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of
Washington, Seattle, WA, USA). Details of HbA1c, fasting serum glucose, total serum
cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol measurement techniques
were reported earlier [12].
Medical history—History of CVD was based on self-reported myocardial infarction,
stroke, transient ischaemic event, percutaneous transluminal coronary angioplasty or
coronary artery bypass graft. All participants reported whether they were current, past or
never smokers.
Depression symptoms and ADM use—Current use of ADMs was assessed when
participants brought all prescription medicines to their randomisation visit. On entry to the
study, participants completed the Beck Depression Inventory (BDI) [13], a scale with
reliable psychometric characteristics across a broad spectrum of both clinical and non-
clinical populations. The BDI lists 21 symptoms, with responses scored from 0 to 3 in
ascending symptom severity, and total scores ranging from 0 to 63. We identified
participants with BDI scores ≥11 as having elevated depression symptoms; others have
chosen scores ranging from 10 to 16, generally as a function of the importance placed on
depression recognition. The cut-off point of 11 was used in the analysis of depression
symptoms in the DPP [14], allowing for direct comparison across the two study populations.
When assessing the association between depression symptoms and CVD risk, we used
continuous BDI scores, as preliminary analyses indicated that dichotomising BDI scores
introduced measurement imprecision that attenuated the associations between depression
symptom scores and CVD risk, and because we found no non-linear associations between
depression symptom scores and CVD risk (results not shown). To permit a more meaningful
interpretation for the association of depression symptoms and CVD risk, the ORs were
calculated based on an accepted criterion for a ‘minimal detectable difference’ [15] in BDI
scores: 0.5 SD of the baseline BDI value. In the current study 0.5 SD= 2.484 BDI score
points. This transformation makes the OR for BDI (the increase in odds of CVD risk
associated with a one-point increase in the recalculated symptom measure) interpretable as
the increase in CVD risk associated with a minimal detectable difference in BDI symptoms.
Risk factor classification—A primary objective of the study was to assess the
association between cardiovascular risk factors and elevated depression symptoms or ADM
use. We considered current smokers, those with BMI ≥30 kg/m2, and those with ABI <0.9
or >1.3 to be ‘at risk’. Both low and high ABI values have been associated with elevated
CVD risk [16]. We also considered to be ‘at risk’ those participants who had HbA1c, BP and
lipid values above treatment targets recommended by the ADA [17] or the Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [18], or who
were taking medicine to achieve these targets [19, 20]. Taking medicine for a risk factor was
regarded as an indicator of the presence of that risk factor, even if that risk factor was
controlled by the medication.
Insulin was the only glucose-lowering agent considered a risk factor because almost all
participants were taking some glucose-lowering medicine. All antihypertensive and all lipid-
lowering agents were considered as risk factors. We also defined a composite CVD risk
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score for each person as the number of risk factors present (of the total of 11 shown later in
Table 2). This composite measure was chosen because standard models for assessing total
CVD risk do not identify as risk factors those conditions that are controlled by medication
(because the impact of a controlled risk factor on CVD outcomes is presumed to be
minimal), whereas we regard these risk factors as outcomes in their own right regardless of
whether they can be controlled by medication.
The association between depression measures and MET values was assessed with MET
values as a continuous variable, because there appear to be no established cut-off points for
defining risk status for this factor. Thus, MET values were not included in the composite
measure.
Statistical analysis
Analyses included all randomised participants and were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA). Bivariate relationships between ADM use and elevated
BDI scores and age, sex, race and education were assessed using χ2 tests and multivariate
logistic regression. We assessed the association of CVD risk measures with BDI scores and
ADM use in three ways. First, we modelled dichotomous cardiovascular risk factors using
multivariate logistic regression to determine their associations with ADM use and
continuous BDI scores. Second, we modelled MET values using sex-specific multivariate
regression models, described in a previous report [10], to determine the association with
continuous BDI scores and ADM use. Third, we modelled the number of risk factors for
each individual (composite risk score, controlled for age, race/ethnicity, education, diabetes
duration and history of CVD) using Poisson regression (which is appropriate for measures
that count numbers of events).
We also performed a series of ancillary analyses for each of the three risk measures
described above (dichotomous risk factors, MET values and composite risk score). First, we
assessed whether there was a statistically significant interaction between depression
symptoms and ADM use, controlled for all other factors, to determine whether associations
were additive. Second, we conducted all regression analyses within the two BDI strata (BDI
<11, ≥11) to see if the relationship between continuous BDI score and CVD risk factors
differed in those with low depression symptoms and those with more symptoms of
depression. Third, we repeated all analyses with loge-transformed BDI scores, because BDI
scores were not normally distributed (most participants had very low scores). Fourth, we
tested for an age interaction with BDI scores and ADM use, because participants as young
as 45 years old were included only during the first year of recruitment, with the lower limit
changing to 55 years thereafter.
Finally, we repeated regression analyses, first including only those participants who were
taking SSRI agents, and then including all participants who were taking any agent other than
a TCA or tetracyclic agent. These analyses examined whether the associations between
SSRI (or any non-TCA or tetracyclic) use and CVD risk factors differed from the
associations between all ADMs combined and CVD risk factors.
Values are mean ± SD unless stated otherwise.
Results
Depression scores and ADM use at baseline
Table 1 shows that on entering the study 16.5% of participants were taking ADMs and
14.7% had BDI scores ≥ 11, probably indicating mild to moderate depression. More than a
quarter of participants (26.8%) had at least one of the two depression markers. Of the
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participants taking ADMs, 57% were taking SSRIs, 24% were taking SNRIs and 19% were
taking TCAs or tetracyclic agents. Depression symptom scores were mostly in the
subclinical range (median = 8, 25th percentile = 6, 75th percentile = 9) in part because many
with severe depression symptoms resulting in hospitalisation or inability to successfully
complete the run-in period were excluded from Look AHEAD participation. Elevated BDI
scores and ADM use were more common among participants who were younger, female or
less educated. Racial/ethnic differences in BDI scores and ADM use were also apparent,
with more American Indians and fewer whites having BDI scores ≥11 and more whites and
fewer African-Americans reporting use of ADMs (Table 1).
Depression symptoms, ADM use and CVD risk factors
Table 2 shows the proportion of participants defined as ‘at risk’ for each CVD risk factor,
with ‘at risk’ defined as having an elevated level or taking medicine for the risk factor.
Table 2 shows that continuous BDI scores were significantly associated with all measures of
BP risk, current smoking and BMI ≥30 kg/m2. Use of ADMs was significantly associated
with all indicators of CVD risk, except for HbA1c ≥7.0% or insulin use and out-of-target
ABI values. In multivariate regression analyses of the association between depression
indicators and MET values (results not shown), BDI scores were negatively associated with
MET values for women (β [SE] = −0.011 [0.005], p<0.05) and for men (β [SE] = −0.027
[0.009], p<0.05), and ADM use was negatively associated with MET values in women (β
[SE] = −0.244 [0.067], p<0.001); in men the association was nearly identical (β [SE] =
−0.232 [0.124], p=0.06), but not statistically significant in this smaller group (owing to the
different covariates in the sex-specific models, we did not test for differences in
coefficients). The mean number of CVD risk factors (of 11) for which an individual
participant was at risk was 7.15 (SD=1.92; minimum = 0, median = 8, maximum = 11).
Modelling the number of risk factors using Poisson regression controlled for age, sex, race/
ethnicity, diabetes duration and history of CVD (results not shown), there was a significant
association with BDI score (p=0.0146) and with ADM use (p=0.0003).
We also conducted a series of ancillary analyses for each of the three risk measures
described above (dichotomous risk factors, MET values and composite risk score), and the
results confirmed the robustness of our original models (results not shown). First, there was
no statistically significant interaction between depression symptoms and ADM use for any
dichotomous risk variable nor for the composite risk score variable. When we added an
interaction term for depression symptoms and ADM use to the models of MET values for
men and women, both of the interactions were statistically significant (p<0.05). In each case,
the association of MET values with each depression factor was stronger (more negative) in
the relative or absolute absence of the other depression factor.
Second, when stratified by BDI score (<11, ≥11), associations of BDI scores with CVD risk
factors in each group were similar to those of the entire study population (results not
shown). BDI score was significantly associated with all measures of BP in both BDI score
groups. In the stratified analysis, BDI score was associated with current smoking only in the
high BDI score group, and with BMI ≥30 kg/m2 only in the low BDI score group.
Third, when we re-ran the models with log-transformed BDI scores we found similar
relationships and almost identical ORs and 95% CIs. Fourth, when we tested for an age
interaction with BDI scores and ADM use we found only one significant interaction (BDI
score and age, with HDL-cholesterol as an outcome; p=0.05). We then re-ran the original
model for HDL-cholesterol, including only those participants 55–76 years old; this analysis
generated the same relationships reported in Table 2.
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Finally, when we repeated the regression analyses (results not shown), first including only
those participants who were taking SSRI agents, and then including all participants who
were taking any agent other than a TCA or tetracyclic agent, the results were nearly identical
to analyses involving individuals taking any ADMs.
Discussion
We hypothesised a significant positive association between depression symptoms and CVD
risk. While we found no such associations for elevated depression symptoms (BDI scores
≥11), we did find that a continuous measure of depression symptoms was significantly
associated with all indicators of hypertension, and with current smoking, BMI ≥30 kg/m2,
higher composite risk scores and lower MET values. This suggests that a continuous
measure may be a better way of conceptualising the association of depression symptoms and
CVD risk indicators, especially since we found no non-linear associations between CVD
risk indicators and depression symptom scores. These findings are consistent with studies
showing that continuous depression symptom severity scores are better predictors of many
diabetes self-care behaviours than categorically defined probable major depression [21]; and
that sub-syndromal depression is associated with cardiac mortality [22]. We also found that
the associations between BDI score and CVD risk factors were similar for those with higher
and lower BDI scores. This suggests that there may be benefit in reducing depression scores
no matter where one is in the distribution of scores—lower is better regardless of one’s
score.
We hypothesised a significant positive association between ADM use and greater CVD risk,
and found many significant associations: ADM use was significantly associated with all
indicators of hypertension and hyperlipidaemia, and with current smoking, BMI ≥30 kg/m2,
higher composite risk scores and lower MET values (i.e. with every risk factor except for
HbA1c ≥7.0% [or insulin use] and out-of-target ABI values).
The fact that our composite index of CVD risk (the number of factors on which a study
participant was at risk) was also significantly associated with both BDI score and ADM use
suggests that the risk is cumulative or global rather than merely associated with different
specific risk factors in different individuals.
Our ancillary analysis findings confirm the robustness of our original models. We found that
the associations of depression symptoms and ADM use generally were independent of one
another; there was a significant interaction in the association of depression symptoms and
ADM use for only one CVD risk factor—MET values. This indicates that the association of
depression symptoms with other CVD risk factors generally was as strong in those taking
ADMs as in those not taking them. We also found that the association of ADM use with
these CVD risk factors was equally strong in those with different levels of depression
symptoms. For the one exception (MET values) the association of CVD risk with each
depression factor was stronger (more negative) in the relative or absolute absence of the
other depression factor. Thus, there was a negative synergy involving a tendency of these
factors to suppress or substitute for each other, and their effects were not strictly additive.
While we do not have an explanation for why synergy was present only for this one CVD
risk factor, nor what might have produced this synergy, the reasons for these findings are
likely to become clearer as we better understand the ways that depression symptoms and
medicines are related to CVD risk.
Other ancillary analyses also confirmed the robustness of our original models. An analysis
using log-transformed BDI scores generated results very similar to our main analysis, as did
a test for age interaction with BDI scores and ADM use. Finally, we found that the
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association between SSRI (or any non-TCA or tetracyclic) use and CVD risk factors was
essentially the same as the association between all ADMs and CVD risk factors.
Elevated depression symptoms could be a cause, consequence or exacerbating agent for
CVD risk. Alternatively, both depression symptoms and CVD risk factors could have a
common cause, such as inflammation. There are several plausible explanations for the
association between ADM use and CVD risk indicators; while the present study does not
allow us to assess their validity, we offer them to stimulate future research to evaluate
possible explanations. First, ADM use may be a marker for more severe, chronic or
recurrent depression in the past. Second, individuals who qualify as having elevated CVD
risk because they take medicines for those conditions might also be more likely to take
ADMs, independently of depression status. Third, some side effects of antihypertensive and
lipid-lowering medicines (e.g. insomnia, tiredness and impotence) may be identified as
symptoms of depression and treated with ADM. Alternatively, as hypothesised, ADMs
might increase BP, lipids and BMI. While weight gain is a recognised side effect of most
ADMs, little is known about the effects of ADMs on BP and lipids.
Study strengths and limitations
This is the first study of which we are aware to assess the association between depression
symptoms or ADM use and CVD risk in people with type 2 diabetes, and to simultaneously
assess the independent association of depression symptoms and ADM use with CVD risk in
any population. Other study strengths include the large, multi-ethnic population and the fact
that depression symptoms, ADM use and a broad range of cardiovascular risk factors were
assessed. Moreover, most CVD risk factors were assessed objectively rather than relying on
self-reporting.
The current study also contributes to the growing literature suggesting that negative health
outcomes may be associated with depression symptoms across the whole range of
depression symptom severity. The fact that few Look AHEAD trial participants had high
levels of depression symptoms allowed for a robust analysis of the association between
subclinical depression symptom scores and CVD risk factors.
The study also has important limitations. It was not a controlled trial assessing the effects of
depression symptoms or ADM use on cardiovascular risk. It was cross-sectional, so we
cannot draw conclusions about causal associations between depression measures and CVD
risk measures.
Another limitation of the study is the fact that we did not confirm that all patients took
ADMs because of depression rather than for other indications, such as smoking cessation,
neuropathic pain or other psychiatric conditions, including panic disorder, social anxiety
disorder, obsessive–compulsive disorder and post-traumatic stress disorder [23]. Further, we
had no information about the dosage or duration of treatment with ADMs. Also, some
participants might have failed to disclose that they were taking ADMs, while others who
reported that they were not taking ADMs may have discontinued them very recently.
However, both of these possibilities would mitigate the likelihood of finding an association
between ADM use and CVD risk factors; therefore they would bias the estimated
associations toward the null hypothesis.
Conclusions
In future analyses, we will assess the temporal dynamics of the relationship of ADM use and
CVD risk factors in Look AHEAD. Longitudinal studies currently underway, such as the
Safety and Efficacy of Sertraline for Depression in Patients with Congestive Heart Failure
Rubin et al. Page 8













(SADHART-CHF) trial [24], could also help clarify the effects of SSRI, the most commonly
prescribed class of ADMs, on cardiac prognosis. Look AHEAD longitudinal studies will
also allow us to assess the association of continuous depression symptoms and elevated
depression symptoms with health risk factors and negative health outcomes.
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AHEAD Action for Health in Diabetes
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ILI Intensive lifestyle intervention
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SNRI Serotonin–noradrenaline reuptake inhibitor
SSRI Selective serotonin reuptake inhibitors
TCA Tricyclic antidepressant
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Table 1
Depression and ADM use by demographic variables of interest
Variable Total (n) BDI ≥ 11(%) On ADMs (%) BDI ≥ 11 or on ADMs (%)
Total 5,145 752 (14.7) 846 (16.5) 1,373 (26.8)
Age (years)
 45–55 1,621 281 (17.4) 309 (19.1) 507 (31.3)
 56–65 2,650 380 (14.4) 432 (16.3) 698 (26.5)
 66–76 874 91 (10.5) 105 (12.0) 168 (19.3)
 p valuea <0.0001 <0.0001 <0.0001
 p valueb 0.0046 <0.0001 <0.0001
Sex
 Male 2,082 218 (10.5) 253 (12.2) 404 (19.4)
 Female 3,063 534 (17.5) 593 (19.4) 969 (31.8)
 p valuea <0.0001 <0.0001 <0.0001
 p valueb 0.001 <0.0001 <0.0001
Race
 African-American/black (not Hispanic) 803 132 (16.5) 67 (8.3) 174 (21.8)
 American Indian/Native American/Alaskan Native 258 70 (27.2) 24 (9.3) 84 (32.7)
 White 3,253 396 (12.2) 657 (20.2) 893 (27.5)
 Hispanic 681 131 (19.2) 75 (11.0) 183 (26.9)
 Asian/Pacific Islander/other/mixed/missing 150 23 (15.3) 23 (15.3) 39 (26.0)
 p valuea <0.0001 <0.0001 0.0033
 p valueb 0.008c <0.0001d <0.0001e
Education
 <13 years 1,024 211 (20.7) 314 (13.1) 308 (30.7)
 13–16 years 1,915 320 (16.8) 345 (18.0) 562 (29.4)
 >16 years 2,094 203 (9.7) 341 (16.3) 468 (22.4)
 p valuea <0.0001 0.0026 <0.0001
 p valueb <0.0001 0.0156 <0.0001
a
p value from χ2 test
b
p value from multivariate logistic regression adjusted for the other three variables in the table
c
Elevated depression symptom scores were more common (test results not shown in table) among American Indian/Native American/Alaskan
Natives than in any other racial/ethnic group (all p<0.01), and elevated BDI scores were more common among African-Americans and Hispanics
than among whites (both p=0.001)
d
ADM use was more common (test results not shown in table) among whites than among African-Americans, Hispanics or American Indian/
Native American/Alaskan Natives (all p<0.001), and ADM use was more common among Asian/Pacific Islanders than among African-Americans
(p<0.01)
e
African-Americans were less likely to have either depression indicator than whites, Hispanics or American Indian/Native American/Alaskan
Natives (all p<0.05)
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